Cytek Biosciences (CTKB) Expected to Post Quarterly Earnings on Wednesday

Cytek Biosciences (NASDAQ:CTKB) will likely be releasing its Q2 2026 results after the market closes on Wednesday, August 5th. Analysts expect Cytek Biosciences to announce earnings of ($0.02) per share and revenue of $47.31 million for the quarter. Individuals can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Wednesday, August 5, 2026 at 4:30 PM ET.

Cytek Biosciences (NASDAQ:CTKB) last posted its quarterly earnings data on Thursday, May 7th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.07). The firm had revenue of $44.13 million during the quarter, compared to analysts’ expectations of $44.23 million. Cytek Biosciences had a negative net margin of 36.25% and a negative return on equity of 10.07%. On average, analysts expect Cytek Biosciences to post $-0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Cytek Biosciences Stock Performance

Shares of CTKB opened at $4.46 on Wednesday. The stock has a market capitalization of $575.96 million, a P/E ratio of -7.82 and a beta of 1.17. Cytek Biosciences has a 1 year low of $3.28 and a 1 year high of $6.18. The company’s fifty day moving average is $4.28 and its two-hundred day moving average is $4.47.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on CTKB shares. Stephens dropped their price target on shares of Cytek Biosciences from $5.50 to $4.75 and set an “overweight” rating on the stock in a research note on Wednesday, May 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cytek Biosciences in a report on Wednesday, June 24th. Finally, Morgan Stanley dropped their target price on Cytek Biosciences from $6.00 to $5.50 and set an “equal weight” rating on the stock in a research report on Tuesday, May 12th. Three research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $5.69.

Hedge Funds Weigh In On Cytek Biosciences

A number of large investors have recently made changes to their positions in the stock. AQR Capital Management LLC boosted its holdings in Cytek Biosciences by 394.4% during the first quarter. AQR Capital Management LLC now owns 653,277 shares of the company’s stock worth $2,620,000 after buying an additional 521,135 shares in the last quarter. Jane Street Group LLC grew its position in Cytek Biosciences by 412.2% during the first quarter. Jane Street Group LLC now owns 344,169 shares of the company’s stock worth $1,380,000 after buying an additional 276,972 shares during the period. Acadian Asset Management LLC purchased a new position in Cytek Biosciences in the first quarter valued at about $162,000. Strs Ohio purchased a new position in Cytek Biosciences in the first quarter valued at about $105,000. Finally, Creative Planning lifted its position in shares of Cytek Biosciences by 455.4% during the 2nd quarter. Creative Planning now owns 55,677 shares of the company’s stock valued at $189,000 after acquiring an additional 45,652 shares during the period. Hedge funds and other institutional investors own 69.46% of the company’s stock.

About Cytek Biosciences

Cytek Biosciences is a biotechnology company specializing in innovative cell analysis solutions. The firm develops and commercializes advanced spectral flow cytometry instruments and associated reagents designed to enable high-parameter single-cell analysis. Its technology platform offers researchers and clinicians enhanced sensitivity, resolution and flexibility compared to traditional flow cytometry methods.

The company’s core product portfolio includes the Aurora and Northern Lights spectral cytometry systems, which support simultaneous detection of up to 64 fluorescence parameters.